Drug-Virus Interaction Investigation Service

In the globalized field of drug development, a deep understanding of the antiviral mechanisms of candidate drugs is crucial. Faced with the emergence of new viruses and variants, researching and developing effective antiviral drugs has become an urgent and complex challenge. This challenge requires not only precise identification of the virus's biological characteristics but also a thorough exploration of how candidate drugs affect the virus's life cycle. Creative Biolabs proudly introduces its specialized drug-virus interaction investigation service, aimed at helping researchers and pharmaceutical companies unveil the mechanisms of action of candidate drugs.

Multidimensional Drug-Virus Interaction Investigation Service

In the field of drug development for viral infectious diseases, Creative Biolabs offers comprehensive services, including the development of drugs against viral infections (such as small interfering RNAs, gene editing tools, antibodies/peptides) and comprehensive antiviral mechanism verification services. Our services cover a wide range of candidate drugs, ensuring that we can meet clients' needs to verify antiviral drugs.

Nucleic Acid-Protein Interaction Detection

• Objective: To validate the intervention mechanism of small interfering RNAs or other gene editing tools against specific viral proteins.
• Methods:
  • Dual-Luciferase Reporter Assay: Assessing the effects of nucleic acid intervention by monitoring gene expression and protein activity.
  • Molecular Docking Analysis: Using computational simulation to predict the binding pattern and affinity between nucleic acids and proteins.
  • Microscale Thermal Diffusion: Precisely measuring the interaction strength and stability between molecules, providing key data for drug design.

Protein-Protein Interaction Detection

• Objective: To validate the intervention mechanism of antibodies or peptides against specific viral proteins.
• Methods:
  • GST-Pull Down and Co-Immunoprecipitation (Co-IP): Identifying direct interactions between proteins through physical methods to reveal potential inhibitory mechanisms.
  • Surface Plasmon Resonance (SPR) Affinity Measurement: Quantitatively assessing the binding strength between proteins and antibodies, providing important reference for drug efficacy evaluation.
  • Molecular Docking Analysis and Microscale Thermal Diffusion: Combining experimental and theoretical methods to deeply understand how drugs interact with target proteins.

Small Molecule Compound-Protein Interaction Detection

• Objective: To study how small molecule compounds interact with specific viral proteins, thereby inhibiting their function.
• Method: SPR affinity measurement technology, used to evaluate the binding characteristics of small molecule compounds with proteins, providing a scientific basis for drug screening and optimization.

Fig.1 Binding avidity evaluation of anti-HAV for serum samples by SPR.^1,2

Creative Biolabs Advantages

• Advanced experimental methods and technologies
• Comprehensive range of services
• High-quality research support
• Accelerating the drug development process

With these advanced experimental methods and technologies, Creative Biolabs can provide comprehensive drug-virus interaction analysis, helping clients make more informed decisions in the development of therapeutic drugs for viral infectious diseases. Our goal is to accelerate the drug development process through high-quality research support, ultimately helping our clients achieve breakthrough treatment methods. We invite you to contact us to support your viral infection disease research projects.

References:

1. Santos, GMCD.; et al. Detection of antibodies against hepatitis a virus (HAV) by a surface plasmon resonance (SPR) biosensor: a new diagnosis tool based on the major HAV capsid protein VP1 (SPR-HAVP1). Sensors (Basel). 2021, 21(9).
2. under Open Access license CC BY 4.0, without modification.

• Virus Pathogenesis and Cell Host Factor